204 related articles for article (PubMed ID: 33258507)
1. AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer.
Hertzog JR; Zhang Z; Bignan G; Connolly PJ; Heindl JE; Janetopoulos CJ; Rupnow BA; McDevitt TM
Prostate; 2020 Oct; 80(14):1223-1232. PubMed ID: 33258507
[TBL] [Abstract][Full Text] [Related]
2. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.
Zhao J; Ning S; Lou W; Yang JC; Armstrong CM; Lombard AP; D'Abronzo LS; Evans CP; Gao AC; Liu C
Mol Cancer Ther; 2020 Aug; 19(8):1708-1718. PubMed ID: 32430485
[TBL] [Abstract][Full Text] [Related]
3. Mesoporous silica nanoparticles combined with AKR1C3 siRNA inhibited the growth of castration-resistant prostate cancer by suppressing androgen synthesis in vitro and in vivo.
Chen J; Yang Y; Xu D; Li J; Wu S; Jiang Y; Wang C; Yang Z; Zhao L
Biochem Biophys Res Commun; 2021 Feb; 540():83-89. PubMed ID: 33450484
[TBL] [Abstract][Full Text] [Related]
4. A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics.
Wangtrakuldee P; Adeniji AO; Zang T; Duan L; Khatri B; Twenter BM; Estrada MA; Higgins TF; Winkler JD; Penning TM
J Steroid Biochem Mol Biol; 2019 Sep; 192():105283. PubMed ID: 30641225
[TBL] [Abstract][Full Text] [Related]
5. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
[TBL] [Abstract][Full Text] [Related]
6. The AKR1C3/AR-V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression.
Wang B; Wu S; Fang Y; Sun G; He D; Hsieh JT; Wang X; Zeng H; Wu K
J Cell Mol Med; 2020 Oct; 24(20):12032-12043. PubMed ID: 32902124
[TBL] [Abstract][Full Text] [Related]
7. Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
Yang JC; Xu P; Ning S; Wasielewski LJ; Adomat H; Hwang SH; Morisseau C; Gleave M; Corey E; Gao AC; Lara PN; Evans CP; Hammock BD; Liu C
Oncogene; 2023 Feb; 42(9):693-707. PubMed ID: 36596844
[TBL] [Abstract][Full Text] [Related]
8. A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer.
Zhou M; Wang X; Xia J; Cheng Y; Xiao L; Bei Y; Tang J; Huang Y; Xiang Q; Huang S
Int J Nanomedicine; 2020; 15():3087-3098. PubMed ID: 32431503
[TBL] [Abstract][Full Text] [Related]
9. ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells.
Powell K; Semaan L; Conley-LaComb MK; Asangani I; Wu YM; Ginsburg KB; Williams J; Squire JA; Maddipati KR; Cher ML; Chinni SR
Clin Cancer Res; 2015 Jun; 21(11):2569-79. PubMed ID: 25754347
[TBL] [Abstract][Full Text] [Related]
10. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
[TBL] [Abstract][Full Text] [Related]
11. Reversal of Apalutamide and Darolutamide Aldo-Keto Reductase 1C3-Mediated Resistance by a Small Molecule Inhibitor.
Morsy A; Trippier PC
ACS Chem Biol; 2020 Mar; 15(3):646-650. PubMed ID: 32125151
[TBL] [Abstract][Full Text] [Related]
12. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.
Park S; Song CS; Lin CL; Jiang S; Osmulski PA; Wang CM; Marck BT; Matsumoto AM; Morrissey C; Gaczynska ME; Chen Y; Mostaghel EA; Chatterjee B
Endocrinology; 2020 Feb; 161(2):. PubMed ID: 31894239
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
Byrns MC; Mindnich R; Duan L; Penning TM
J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
[TBL] [Abstract][Full Text] [Related]
15. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H
Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486
[TBL] [Abstract][Full Text] [Related]
16. 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer.
Barnard M; Quanson JL; Mostaghel E; Pretorius E; Snoep JL; Storbeck KH
J Steroid Biochem Mol Biol; 2018 Oct; 183():192-201. PubMed ID: 29936123
[TBL] [Abstract][Full Text] [Related]
17. AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer.
Liu C; Yang JC; Armstrong CM; Lou W; Liu L; Qiu X; Zou B; Lombard AP; D'Abronzo LS; Evans CP; Gao AC
Mol Cancer Ther; 2019 Oct; 18(10):1875-1886. PubMed ID: 31308078
[TBL] [Abstract][Full Text] [Related]
18. DAB2IP regulates intratumoral testosterone synthesis and CRPC tumor growth by ETS1/AKR1C3 signaling.
Gu Y; Wu S; Chong Y; Guan B; Li L; He D; Wang X; Wang B; Wu K
Cell Signal; 2022 Jul; 95():110336. PubMed ID: 35452821
[TBL] [Abstract][Full Text] [Related]
19. Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer.
Wu M; Zhang R; Zhang Z; Zhang N; Li C; Xie Y; Xia H; Huang F; Zhang R; Liu M; Li X; Cen S; Zhou J
Elife; 2023 Jan; 12():. PubMed ID: 36656639
[TBL] [Abstract][Full Text] [Related]
20. UGT2B17 Expedites Progression of Castration-Resistant Prostate Cancers by Promoting Ligand-Independent AR Signaling.
Li H; Xie N; Chen R; Verreault M; Fazli L; Gleave ME; Barbier O; Dong X
Cancer Res; 2016 Nov; 76(22):6701-6711. PubMed ID: 27659047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
